The Effects of Pro-Inflammatory and Anti-Inflammatory Agents for the Suppression of Intimal Hyperplasia: An Evidence-Based Review

Abstract

Anti-atherogenic therapy is crucial in halting the progression of inflammation-induced intimal hyperplasia. The aim of this concise review was to methodically assess the recent findings of the different approaches, mainly on the recruitment of chemokines and/or cytokine and its effects in combating the intimal hyperplasia caused by various risk factors. Pubmed and Scopus databases were searched, followed by article selection based on pre-set inclusion and exclusion criteria. The combination of keywords used were monocyte chemoattractant protein-1 OR MCP-1 OR TNF-alpha OR TNF-α AND hyperplasia OR intimal hyperplasia OR neointimal hyperplasia AND in vitro. These keywords combination was incorporated in the study and had successfully identified 77 articles, with 22 articles were acquired from Pubmed, whereas 55 articles were obtained from Scopus. However, after title screening, only twelve articles meet the requirements of defined inclusion criteria. We classified the data into 4 different approaches, i.e., utilisation of natural product, genetic manipulation and protein inhibition, targeted drugs in clinical setting, and chemokine and cytokines induction. Most of the articles are working on genetic manipulation targeted on specific pathway to inhibit the pro-inflammatory factors expression. We also found that the utilisation of chemokine- and cytokine-related treatments are emerging throughout the years. However, there is no study utilising the combination of approaches that might give a better outcome in combating intimal hyperplasia. Hopefully, this concise review will provide an insight regarding the usage of different novel approaches in halting the progression of intimal hyperplasia, which serves as a key factor for the development of atherosclerosis in cardiovascular disease.

The Impact of Oxidative Stress in Human Pathology: Focus on Gastrointestinal Disorders

“…As far as smooth muscle was concerned, most of the data are related to lung and vascular diseases. In fact, many experimental data showed that vascular smooth muscle cells are involved, together with endothelial cells, in the development of atherosclerosis, a pathology characterized by persistent inflammation and oxidative stress [ 150 ].…”

Heparin/Collagen-REDV Modification of Expanded Polytetrafluoroethylene Improves Regional Anti-thrombosis and Reduces Foreign Body Reactions in Local Tissues

“…Regardless of the type of foreign material or where it is placed in the body, the consequence of a FBR is the same: fibrotic hyperplasia, an important factor in the development of stenosis in tissues with implants ( Klopfleisch and Jung, 2017 ; Jeong et al, 2020 ). This explains why stenosis frequently occurs following ePTFE implantation, even among patients receiving anticoagulant therapy ( Che Man et al, 2020 ). Macrophages are key participants in the FBR caused by biomaterial implantation, and the macrophage phenotype can change in response to alterations of the microenvironment ( Chu et al, 2020 ).…”

Long Non-Coding RNAs (lncRNAs) in Cardiovascular Disease Complication of Type 2 Diabetes

“…Eventually, this event leads to high production of inflammatory cytokines and chemokines together with excessive release of the reactive oxygen species (ROS) and AGEs, thus activating the nuclear factor-κB (NFκB), activator protein-1 (AP-1), endothelin-1 (ET-1, a vasoconstrictive signal), pro-thrombotic tissue factors, and plasminogen activator inhibitor-1 (PAI-1) [ 100 , 101 , 102 ]. The increased levels of these molecules contribute to inflammation, vasoconstriction, and thrombosis [ 100 , 101 , 102 ]. Additionally, the presence of insulin resistance also contributes to greater ROS production [ 103 ].…”